SK282022B6 - Tetrahydronaftalénamíny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie ako liečiv - Google Patents

Tetrahydronaftalénamíny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie ako liečiv Download PDF

Info

Publication number
SK282022B6
SK282022B6 SK1485-97A SK148597A SK282022B6 SK 282022 B6 SK282022 B6 SK 282022B6 SK 148597 A SK148597 A SK 148597A SK 282022 B6 SK282022 B6 SK 282022B6
Authority
SK
Slovakia
Prior art keywords
ome
free base
acid salt
alkyl
compound
Prior art date
Application number
SK1485-97A
Other languages
English (en)
Slovak (sk)
Other versions
SK148597A3 (en
Inventor
Robert Swoboda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10774032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK282022(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SK148597A3 publication Critical patent/SK148597A3/sk
Publication of SK282022B6 publication Critical patent/SK282022B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
SK1485-97A 1995-05-05 1996-05-03 Tetrahydronaftalénamíny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie ako liečiv SK282022B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9509156.7A GB9509156D0 (en) 1995-05-05 1995-05-05 Organic compounds
PCT/EP1996/001841 WO1996034849A1 (en) 1995-05-05 1996-05-03 Tetralines bearing a phenyl substituant on the aromatic ring and their use in the treatment of epilepsy, stroke and brain or spinal trauma

Publications (2)

Publication Number Publication Date
SK148597A3 SK148597A3 (en) 1998-10-07
SK282022B6 true SK282022B6 (sk) 2001-10-08

Family

ID=10774032

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1485-97A SK282022B6 (sk) 1995-05-05 1996-05-03 Tetrahydronaftalénamíny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie ako liečiv

Country Status (33)

Country Link
US (1) US6169116B1 (fi)
EP (1) EP0823892B1 (fi)
JP (1) JP3194965B2 (fi)
KR (1) KR100435009B1 (fi)
CN (1) CN1122019C (fi)
AR (1) AR004484A1 (fi)
AT (1) ATE193884T1 (fi)
AU (1) AU706392B2 (fi)
BR (1) BR9608169A (fi)
CA (1) CA2217855C (fi)
CO (1) CO4440486A1 (fi)
CZ (1) CZ292022B6 (fi)
DE (1) DE69608891T2 (fi)
DK (1) DK0823892T3 (fi)
ES (1) ES2148772T3 (fi)
FI (1) FI973530A (fi)
GB (1) GB9509156D0 (fi)
GR (1) GR3033715T3 (fi)
HK (1) HK1014929A1 (fi)
HU (1) HUP9801068A3 (fi)
IL (1) IL118141A (fi)
MX (1) MX9708510A (fi)
NO (1) NO308948B1 (fi)
NZ (1) NZ308471A (fi)
PE (1) PE54797A1 (fi)
PL (1) PL182857B1 (fi)
PT (1) PT823892E (fi)
RU (1) RU2169727C2 (fi)
SK (1) SK282022B6 (fi)
TR (1) TR199701298T1 (fi)
TW (1) TW359667B (fi)
WO (1) WO1996034849A1 (fi)
ZA (1) ZA963540B (fi)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1458386B1 (en) * 2001-12-27 2007-04-18 Ortho-McNeil Pharmaceutical, Inc. Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2005037286A1 (en) 2003-03-25 2005-04-28 Vasopharm Biotech Gmbh Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia
EP1956006A1 (en) 2007-02-06 2008-08-13 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments
WO2008154044A1 (en) * 2007-06-15 2008-12-18 University Of Florida Research Foundation Therapeutic compounds and methods of use
EP2011786A1 (en) * 2007-07-05 2009-01-07 Laboratorios del Dr. Esteve S.A. Indane-amine derivatives, their preparation and use as medicaments
CN106573872B (zh) * 2014-05-19 2021-07-20 东北大学 5-羟色胺受体靶向化合物和方法
AU2021329920A1 (en) * 2020-08-19 2023-04-27 Northeastern University Serotonin receptor modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6045179B2 (ja) * 1977-06-08 1985-10-08 フナイ薬品工業株式会社 新規環状アミノアルコ−ル類およびその製造法
EP0257285A3 (en) 1986-07-28 1989-12-27 Whitby Research Incorporated Method and compositions for reducing the intraocular pressure of mammals
DE3718317A1 (de) 1986-12-10 1988-06-16 Bayer Ag Substituierte basische 2-aminotetraline
EP0381902A1 (en) 1989-01-09 1990-08-16 Merrell Dow Pharmaceuticals Inc. Tetralin derivatives
JP2931986B2 (ja) 1989-02-17 1999-08-09 武田薬品工業株式会社 アラルキルアミン誘導体
SE8901889D0 (sv) 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
ES2138639T3 (es) 1993-08-27 2000-01-16 Hoffmann La Roche Derivados peptidicos de tetrahidronaftaleno.
FR2711139B1 (fr) 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
ZA963540B (en) 1997-11-03
NO975087D0 (no) 1997-11-04
PT823892E (pt) 2000-11-30
HUP9801068A3 (en) 2000-02-28
JP3194965B2 (ja) 2001-08-06
EP0823892A1 (en) 1998-02-18
AU5812996A (en) 1996-11-21
FI973530A (fi) 1997-11-04
TW359667B (en) 1999-06-01
RU2169727C2 (ru) 2001-06-27
NZ308471A (en) 1999-01-28
DE69608891D1 (de) 2000-07-20
DE69608891T2 (de) 2000-11-16
PL323037A1 (en) 1998-03-02
IL118141A0 (en) 1996-09-12
KR100435009B1 (ko) 2004-08-16
TR199701298T1 (xx) 1998-02-21
WO1996034849A1 (en) 1996-11-07
FI973530A0 (fi) 1997-08-27
CN1183763A (zh) 1998-06-03
AR004484A1 (es) 1998-12-16
HK1014929A1 (en) 1999-10-08
CA2217855A1 (en) 1996-11-07
NO308948B1 (no) 2000-11-20
SK148597A3 (en) 1998-10-07
US6169116B1 (en) 2001-01-02
CN1122019C (zh) 2003-09-24
CZ348697A3 (cs) 1998-02-18
MX9708510A (es) 1998-03-31
PL182857B1 (pl) 2002-03-29
PE54797A1 (es) 1998-01-21
BR9608169A (pt) 1999-02-09
KR19990008301A (ko) 1999-01-25
CZ292022B6 (cs) 2003-07-16
ES2148772T3 (es) 2000-10-16
EP0823892B1 (en) 2000-06-14
GB9509156D0 (en) 1995-06-28
DK0823892T3 (da) 2000-10-02
ATE193884T1 (de) 2000-06-15
GR3033715T3 (en) 2000-10-31
HUP9801068A2 (hu) 1999-05-28
JPH10513479A (ja) 1998-12-22
CA2217855C (en) 2008-12-09
IL118141A (en) 2002-11-10
AU706392B2 (en) 1999-06-17
CO4440486A1 (es) 1997-05-07
NO975087L (no) 1997-11-04

Similar Documents

Publication Publication Date Title
US4094992A (en) Benzylidene derivatives
DE69432984T2 (de) Therapeutische substituierte guanidine
EP3610874A1 (en) Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
CH660484A5 (de) In 1-stellung durch einen heterocyclischen rest substituierte 4-((2,5-pyrrolidindion-1-yl)alkyl)piperazin-verbindungen.
PL148590B1 (en) Method of obtaining novel derivatives of 2-amino-5-hydroxy-4-methylpyrimidine
US6232314B1 (en) Arylalkylpiperazine compounds as antioxidants
JPH09500883A (ja) α１Ａ−アドレナリン受容体アンタゴニストとしてのピペラジン誘導体
ZA200206956B (en) Derivatives of quinoline as alpha-2 antagonists.
RU2727194C2 (ru) Гетероциклические соединения для лечения заболевания
SK282022B6 (sk) Tetrahydronaftalénamíny, spôsob ich prípravy, farmaceutické prostriedky, ktoré ich obsahujú a ich použitie ako liečiv
US20090182025A1 (en) Substituted carboxamides
PL194745B1 (pl) Podstawiony 2-benzyloamino-2-fenylo-acetamid, zawierająca go kompozycja farmaceutyczna i zastosowanie
US8748422B2 (en) Pharmaceutical compositions containing quinazoline derivatives for treating as serotonin receptor antagonist
US20210332046A1 (en) Nicotinic acetylcholine receptor silent agonists
AU2004276128B2 (en) Amide-type carboxamide derivatives
FR2593818A1 (fr) Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
SI9300217A (sl) Farmacevtiki, ki vsebujejo ariloksialkilamino in ariltioalkilamino derivate
US5331007A (en) Arylalkyl-amines and -amides having anticonvulsant and neuroprotective properties
US4703048A (en) Novel 1-benzhydryl-4-cinnamylpiperazine derivatives, and pharmaceutical compositions comprising said compounds as active ingredient for treating a cerebrovascular disease
SK6412000A3 (en) Biphenyl derivatives as pharmaceuticals
EP0381508B1 (en) Use of cinnamamide for relaxing muscle tone
KR100307660B1 (ko) 도파민재소비저해제
RU2339627C2 (ru) Новые арилпиперазиниловые соединения
IE60110B1 (en) 2,5-Pyrrolidinedione derivatives useful as antiarrhythmic agents
CS258133B2 (cs) Způsob výroby l-heteroaryl-4-[(2,5-pyrrolidindion-l-yl)alkyl]- piperazinových derivátů